Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2407 January 2025

APPLICANT (stamp or sticker acceptable)				r sticker acceptable)	PATIENT NHI:	REFERRER Reg No:			
Reg No:					First Names:	First Names:			
Name:					Surname:	Surname:			
Address:					DOB:	Address:			
					Address:				
Fax N	umbei	r:				Fax Number:			
Lenv	atini	b							
Appli	cation	is from	any k bo	The patient has locally advarding and the patient must have synthesis and the patient must progress cannot be achieved by the	ith lenvatinib and met all remaining criteria prior to conneed or metastatic differentiated thyroid cancer inptomatic progressive disease prior to treatment live disease at critical anatomical sites with a high risk other measures  e uptake in a RAI scan  RAI greater than or equal to 600 mCi progression after a RAI treatment within 12 months progression after two RAI treatments administered within the progression after two RAI treatments administered with ghormone (TSH) adequately supressed in radiotherapy with curative intent prioritical contents and the contents administered with the curative intent prioritical contents and the contents and the curative intents and the contents and the curative intents are contents and the curative intents and the curative intents are curative intents.	c of morbidity or mortality where local control			
Renewal — thyroid cancer									
Current approval Number (if known):									
Applications from any relevant practitioner. Approvals valid for 6 months.  Prerequisites(tick box where appropriate)									
There is no evidence of disease progression									

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2407 January 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:						
Reg No:	First Names:	First Names:						
Name:	Surname:	Surname:						
Address:	DOB:	Address:						
	Address:							
Fax Number:		Fax Number:						
Lenvatinib - continued								
Prerequisites(tick boxes where appropriate)	vals valid for 6 months.							
and								
Patient has preserved liver function (Childs-Pugh A)								
	TACE) is unsuitable							
Patient has an ECOG performanc	e status of 0-2							
	emic therapy for their disease in the palliative setting							
Panawal upracostable handtocallular carein	oma							
•								
Applications from any relevant practitioner. Appro								
Prerequisites(tick box where appropriate)								
There is no evidence of disease progres	sion							
Initial application — renal cell carcinoma Applications from any relevant practitioner. Approvals valid for 4 months.  Prerequisites(tick boxes where appropriate)								
· · · · · · · · · · · · · · · · · · ·	enal cell carcinoma							
The disease is of predomina	ant clear-cell histology							
The patient has documented	d disease progression following one previous line of t	reatment						
The patient has an ECOG p	erformance status of 0-2							
	ombination with everolimus							
and		ent of metastatic renal cell carcinoma						
and								
Lenvatinib is to be used in c	ombination with everolimus							
There is no evidence of dise	ease progression							
Applications from any relevant practitioner. Approvals valid for 6 months.  Prerequisites(tick boxes where appropriate)  Patient has unresectable hepatocellular carcinoma and Patient has preserved liver function (Childs-Pugh A) and Transarterial chemoembolisation (TACE) is unsuitable Patient has an ECOG performance status of 0-2 and Patient has not received prior systemic therapy for their disease in the palliative setting  Renewal — unresectable hepatocellular carcinoma  Current approval Number (if known):								

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 3 Form SA2407 January 202F

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:						
Reg No:	First Names:	First Names:						
Name:	Surname:	Surname:						
Address:	DOB:	Address:						
	Address:							
Fax Number:		Fax Number:						
Lenvatinib - continued								
Renewal — renal cell carcinoma								
Current approval Number (if known):								
Applications from any relevant practitioner. Approvals valid for 4 months.  Prerequisites(tick box where appropriate)								
There is no evidence of disease progression								

I confirm the above details are correct and that in signing this form I understand I may be audited.